Weinstock Matthew, Rosenblatt Jacalyn, Avigan David
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Mol Ther Methods Clin Dev. 2017 Mar 18;5:66-75. doi: 10.1016/j.omtm.2017.03.004. eCollection 2017 Jun 16.
Dendritic cells (DCs) are potent antigen-presenting cells that constitute a major component of the immune system's role in the recognition, elimination, and tolerance of cancer. The unique immunologic capabilities of DCs have recently been harnessed for therapeutic use with the creation of DC-based anti-tumor vaccines, several of which have moved into testing in clinical trials for hematologic malignancies. This review summarizes how treatment strategies using DC-based anti-tumor vaccines are advancing immunotherapeutic options for these diseases.
树突状细胞（DCs）是强大的抗原呈递细胞，是免疫系统在癌症识别、消除和耐受过程中发挥作用的主要组成部分。DCs独特的免疫能力最近已被用于治疗，即研发基于DC的抗肿瘤疫苗，其中几种已进入血液系统恶性肿瘤的临床试验测试阶段。本综述总结了使用基于DC的抗肿瘤疫苗的治疗策略如何推进这些疾病的免疫治疗选择。
